AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2536255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1111913 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days
Number of subjects: 120
Study 1111913 — intervention group
Group type: COMPARATOR
Intervention: DTIC 300 mg/m2/day x 6 given every 30 days
Number of subjects: 120
Study 1111913 — intervention group
Group type: COMPARATOR
Intervention: DTIC 100 mg/m2/8 hours x 18 given every 30 days
Number of subjects: 120
Study 31291969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (hRT) with protons (57.0/3.0 Gy RBE)
Number of subjects: 897
Study 31291969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (hRT) with photons (57.0/3.0 Gy)
Number of subjects: 897
Study 31291969 — intervention group
Group type: COMPARATOR
Intervention: Normofractionated radiotherapy (nRT) with photons (70.0/2.0 Gy)
Number of subjects: 897
Study 28464042 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd for six months (long-term)
Number of subjects: 56
Study 28464042 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd for six months (short-course)
Number of subjects: 56
Study 28464042 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd for six months
Number of subjects: 56
Study 28464042 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 56
Study 26639505 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Worm (herbal medicine)
Number of subjects: 190
Study 26639505 — intervention group
Group type: COMPARATOR
Intervention: Mebandazole (allopathic drug)
Number of subjects: 190
Study 23760288 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blockade
Number of subjects: 27
Study 23760288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16487437 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 2
Study 16487437 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 2
Study 14530608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ACTH test (LDAT) 0.5 microg/m2
Number of subjects: 29
Study 14530608 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ACTH test (SDAT) 250 microg/m2
Number of subjects: 29
Study 14530608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ACTH test (LDAT)
Number of subjects: 29
Study 14530608 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ACTH test (SDAT)
Number of subjects: 29
Study 10333674 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inpatient geriatrics unit
Number of subjects: 0
Study 10333674 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 8955660 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 27
Study 8955660 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 27
Study 1896702 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate
Number of subjects: 82
Study 1896702 — intervention group
Group type: COMPARATOR
Intervention: Telfa
Number of subjects: 82
Study 6819275 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron therapy (20 daily fractions over four weeks)
Number of subjects: 192
Study 6819275 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy (20 daily fractions over four weeks)
Number of subjects: 192
Study 6819275 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 192
Study 6819275 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 192
Study 31932116 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 31932116 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 28365896 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation (VR)
Number of subjects: 63
Study 28365896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 25054347 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular mobilization
Number of subjects: 66
Study 25054347 — intervention group
Group type: COMPARATOR
Intervention: Sham scapular mobilization
Number of subjects: 66
Study 25054347 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise
Number of subjects: 66
Study 25054347 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 66
Study 24427694 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (group ESM, n = 26)
Number of subjects: 52
Study 24427694 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine (NTG, group NTG, n = 26)
Number of subjects: 52
Study 21525191 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D (CaD) supplements: 500 mg calcium carbonate plus 200 IU vitamin D(3) twice daily (1000 mg and 400 IU daily, respectively) for an average of 7.0 years.
Number of subjects: 36282
Study 21525191 — intervention group
Group type: COMPARATOR
Intervention: Placebo group for an average of 7.0 years.
Number of subjects: 36282
Study 18647282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mechanism coating comprising pH-responsive enteric polymer (Eudragit S) and biodegradable polysaccharide (resistant starch)
Number of subjects: 8
Study 18647282 — intervention group
Group type: COMPARATOR
Intervention: Control conditions: (i) without food, (ii) with breakfast, (iii) 30 min before breakfast
Number of subjects: 8
Study 16633226 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 61
Study 16633226 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (control)
Number of subjects: 61
Study 14694836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 10840538 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil/Propofol (R/P)
Number of subjects: 60
Study 10840538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/Fentanyl (S/F)
Number of subjects: 60
Study 8814649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.55 g/kg)
Number of subjects: 10
Study 8814649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8814649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.55 g/kg) with deviant tones
Number of subjects: 10
Study 1325036 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g once orally)
Number of subjects: 457
Study 1325036 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg orally twice daily for seven days)
Number of subjects: 457
Study 6677078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive urge control maintenance condition
Number of subjects: 94
Study 6677078 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers
Number of subjects: 94
Study 6677078 — intervention group
Group type: COMPARATOR
Intervention: Relapsers
Number of subjects: 94
Study 31441430 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Records on iPhone
Number of subjects: 0
Study 30266729 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose RS2 (48 g daily for 2 weeks)
Number of subjects: 12
Study 30266729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose RS2 (3 g/2,500 kcal daily for 2 weeks)
Number of subjects: 12
Study 26691409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia Level 2 (HH, FiO2 = 12.6%)
Number of subjects: 25
Study 26691409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia Level 1 (HL, FiO2 = 16%)
Number of subjects: 25
Study 26691409 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NR, FiO2 = 21%)
Number of subjects: 25
Study 25178924 — intervention group
Group type: EXPERIMENTAL
Intervention: O₃ (0.300 ppm) + DE (300 μg/m³)
Number of subjects: 15
Study 25178924 — intervention group
Group type: COMPARATOR
Intervention: O₃ (0.300 ppm)
Number of subjects: 15
Study 25178924 — intervention group
Group type: COMPARATOR
Intervention: DE (300 μg/m³)
Number of subjects: 15
Study 25178924 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 15
Study 25178924 — intervention group
Group type: EXPERIMENTAL
Intervention: O₃ (0.300 ppm) after DE exposure
Number of subjects: 15
Study 21942262 — intervention group
Group type: COMPARATOR
Intervention: bupropion (300 mg/day)
Number of subjects: 58
Study 21942262 — intervention group
Group type: COMPARATOR
Intervention: varenicline (2 mg/day)
Number of subjects: 58
Study 21942262 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 58
Study 19623601 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 6 weeks, then 10 mg/day thereafter
Number of subjects: 885
Study 19623601 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil initiated during the extension study
Number of subjects: 885
Study 19623601 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 885
Study 17305413 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium 12.5mg tablets
Number of subjects: 13
Study 17305413 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium 25mg (2 tablets)
Number of subjects: 13
Study 17305413 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium (up to 75mg/day)
Number of subjects: 13
Study 17305413 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium and ibuprofen
Number of subjects: 13
Study 17305413 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium
Number of subjects: 13
Study 15863458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral tetrahedron (MT) assessment
Number of subjects: 58
Study 15863458 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system employing parameters of the whole MT
Number of subjects: 58
Study 12066736 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 4% amethocaine gel (Ametop)
Number of subjects: 100
Study 12066736 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine infiltration
Number of subjects: 100
Study 10223780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg to 20 mg for 8 weeks)
Number of subjects: 15
Study 10223780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8665994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg suriclone
Number of subjects: 15
Study 8665994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg suriclone
Number of subjects: 15
Study 8665994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg suriclone
Number of subjects: 15
Study 8665994 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 15
Study 8665994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2193503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meals
Number of subjects: 7
Study 2193503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meals
Number of subjects: 7
Study 2193503 — intervention group
Group type: COMPARATOR
Intervention: Fasting (15-24 h)
Number of subjects: 7
Study 486351 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐type therapists with schizophrenics
Number of subjects: 235
Study 486351 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐type therapists with non‐schizophrenics
Number of subjects: 235
Study 486351 — intervention group
Group type: COMPARATOR
Intervention: Short hospitalization
Number of subjects: 235
Study 486351 — intervention group
Group type: COMPARATOR
Intervention: Long hospitalization
Number of subjects: 235
Study 31323594 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on left inferior parietal lobe (rTMS‐lIPL)
Number of subjects: 20
Study 31323594 — intervention group
Group type: COMPARATOR
Intervention: rTMS on left dorsolateral prefrontal cortex (rTMS‐lDLPFC; control condition)
Number of subjects: 20
Study 28659133 — intervention group
Group type: EXPERIMENTAL
Intervention: Study mouthwash A
Number of subjects: 504
Study 28659133 — intervention group
Group type: COMPARATOR
Intervention: Study mouthwash B
Number of subjects: 504
Study 26307376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 2876
Study 26307376 — intervention group
Group type: COMPARATOR
Intervention: No IPC (Control)
Number of subjects: 2876
Study 23342332 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-based airflow system
Number of subjects: 15
Study 23342332 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation with Teflon curettes
Number of subjects: 15
Study 21289263 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) (2500 kJ/d)
Number of subjects: 35
Study 19178124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDT) with peripheral blood stem cell transplant (PBSCT) support
Number of subjects: 197
Study 19178124 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy regimen (CHOP)
Number of subjects: 197
Study 16904589 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intra-articular suction drain
Number of subjects: 118
Study 16904589 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 118
Study 15388963 — intervention group
Group type: EXPERIMENTAL
Intervention: Difructose anhydride III (DFAIII)
Number of subjects: 13
Study 15388963 — intervention group
Group type: COMPARATOR
Intervention: Palatinose
Number of subjects: 13
Study 11245649 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation mapping technique
Number of subjects: 76
Study 11245649 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site atrial potential analysis
Number of subjects: 76
Study 11245649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods combined
Number of subjects: 76
Study 9413023 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (gammahydroxy butyric acid) at a dose of 25 mg/kg body weight
Number of subjects: 20
Study 9413023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8877214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon pharyngeal packing
Number of subjects: 120
Study 8877214 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze pharyngeal packing
Number of subjects: 120
Study 8877214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no packing)
Number of subjects: 120
Study 3464742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 50
Study 3464742 — intervention group
Group type: COMPARATOR
Intervention: Stomatognathic treatment
Number of subjects: 50
Study 31292752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 23
Study 31292752 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian Diet (VD)
Number of subjects: 23
Study 30134956 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 76
Study 30134956 — intervention group
Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 76
Study 27173471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-exposure (1 hour/day for 6 weeks)
Number of subjects: 28
Study 27173471 — intervention group
Group type: COMPARATOR
Intervention: Control (avoiding cold exposure for 6 weeks)
Number of subjects: 28
Study 24948347 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release cysteamine bitartrate (DR-CYS)
Number of subjects: 40
Study 22399575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with TENS device
Number of subjects: 30
Study 22399575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with cryotherapy
Number of subjects: 30
Study 22399575 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 30
Study 20423222 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine (11.86 mg or 5.93 mg of tocopherol)
Number of subjects: 680
Study 20423222 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 680
Study 20423222 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine
Number of subjects: 680
Study 20423222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AS03-adjuvanted and nonadjuvanted vaccines
Number of subjects: 680
Study 19002338 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen with very high protection level against UVB and UVA (containing Tinosorb M, Tinosorb S, and butyl methoxydibenzoylmethane) applied to the left dorsal forearm.
Number of subjects: 12
Study 19002338 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the right dorsal forearm.
Number of subjects: 12
Study 15933483 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 21
Study 15933483 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 11784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (HR per 10 mm Hg increase)
Number of subjects: 6166
Study 11784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular smoking
Number of subjects: 6166
Study 11784224 — intervention group
Group type: EXPERIMENTAL
Intervention: High daily alcohol intake
Number of subjects: 6166
Study 11784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (HR per 1 mmol/L increase)
Number of subjects: 6166
Study 11784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity during leisure time
Number of subjects: 6166
Study 11784224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol level
Number of subjects: 6166
Study 10362188 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 125
Study 10362188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose argatroban
Number of subjects: 125
Study 10362188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose argatroban
Number of subjects: 125
Study 7726441 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms/kg
Number of subjects: 120
Study 7726441 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 120
Study 7726441 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 2187701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 100 mg once daily
Number of subjects: 10
Study 2187701 — intervention group
Group type: COMPARATOR
Intervention: Carteolol 10 mg once daily
Number of subjects: 10
Study 7243513 — intervention group
Group type: EXPERIMENTAL
Intervention: Moved to cribs from heated incubators (Group A: 1,600-1,700 gm; Group B: 1,800-1,900 gm)
Number of subjects: 14
Study 6500777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine teprosilate (Teproside) administered intravenously (i.v.)
Number of subjects: 10
Study 6500777 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously (i.v.)
Number of subjects: 10
Study 30696387 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training (high-LT; 70-85% of maximum predicted heart rate; n=6)
Number of subjects: 13
Study 30696387 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity locomotor training (low-LT; 50-65% of maximum predicted heart rate; n=7)
Number of subjects: 13
Study 29596044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein meal (HP)
Number of subjects: 24
Study 29596044 — intervention group
Group type: COMPARATOR
Intervention: High-Monounsaturated Fat meal (HMF)
Number of subjects: 24
Study 27310969 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) at 5 mg/kg administered at weeks 0, 2, 6, and every 8 weeks thereafter until week 46; dose increased to 10 mg/kg for inadequate responders after week 30
Number of subjects: 18
Study 24047799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix vaccine
Number of subjects: 102074
Study 24047799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102074
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.3 mg/kg, max. 15 mg)
Number of subjects: 90
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Nitrous oxide (N(2)O)
Number of subjects: 90
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Nitrous oxide (N(2)O)
Number of subjects: 90
Study 22677811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sedation)
Number of subjects: 90
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth-retarded children
Number of subjects: 90
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 90
Study 22677811 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose of N(2)O (10%)
Number of subjects: 90
Study 20211292 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18206
Study 20211292 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18206
Study 18798399 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav‐Ladach technique
Number of subjects: 48
Study 18798399 — intervention group
Group type: COMPARATOR
Intervention: Traditional cesarean section
Number of subjects: 48
Study 16103236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach)
Number of subjects: 11
Study 16103236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 11
Study 16103236 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 11
Study 16103236 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1)
Number of subjects: 11
Study 16103236 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (ET-1 receptor blockade)
Number of subjects: 11
Study 11818934 — intervention group
Group type: EXPERIMENTAL
Intervention: New mechanical puncture echoendoscope
Number of subjects: 20
Study 11818934 — intervention group
Group type: COMPARATOR
Intervention: Standard linear echoendoscope
Number of subjects: 20
Study 11818934 — intervention group
Group type: COMPARATOR
Intervention: Conventional radial scanning echoendoscope
Number of subjects: 20
Study 10853111 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation of the vagus nerve (VNS) during the E05 trial
Number of subjects: 199
Study 10853111 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation of the vagus nerve (VNS) during the XE5 trial
Number of subjects: 199